HERON THERAPEUTICS, INC. /DE/ (HRTX) Total liabilities 2016–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) total liabilities at each fiscal year-end, per SEC filings.
$241.5MFY2025 · since FY2016: $88.7M → $241.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $241.5M | -9.5% |
| FY2024 | $266.8M | +4.0% |
| FY2023 | $256.5M | +8.0% |
| FY2022 | $237.4M | +4.1% |
| FY2021 | $228.1M | +94.9% |
| FY2020 | $117.1M | +7.5% |
| FY2019 | $108.9M | +18.4% |
| FY2018 | $92.0M | -10.8% |
| FY2017 | $103.2M | +16.3% |
| FY2016 | $88.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Net marginHRTX Gross profitHRTX Gross marginHRTX Operating incomeHRTX Operating marginHRTX Operating cash flowHRTX Free cash flowHRTX Capital expendituresHRTX Return on equityHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Shareholders’ equityHRTX overview →